Generic medications in ophthalmology

Zore, Matt; Harris, Alon; Tobe, Leslie; Siesky, Brent; Janulevičienė, Ingrida; Behzadi, Jennifer; Amireskandari, Annahita; Egan, Patrick; Garff, Kevin; Wirostko, Barbara

doi:10.1136/bjophthalmol-2012-302245

Cited by 22 publications

(21 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We read the article on ‘Generic medications in ophthalmology’ by Zore et al 1 with great interest. The authors comprehensively describe the regulations that ensure ‘equivalence’ of generic products with branded versions.…”

mentioning

confidence: 99%

Authors' response: generic medications in ophthalmology

Connor

Fraser

2013

Br J Ophthalmol

View full text Add to dashboard Cite

mentioning

confidence: 99%

Authors' response: generic medications in ophthalmology

Connor

Fraser

2013

Br J Ophthalmol

View full text Add to dashboard Cite

“…For example, in a recent review, Zore et al . note the influence of the bottle tip design on the dose of topical ophthalmic preparations delivered to the eye, with drop size varying substantially between generic manufacturers of eye drops and causing different amounts of drug to be delivered to the eye .…”

Section: Defective Drug Formulationmentioning

confidence: 99%

Substandard drugs: a potential crisis for public health

Johnston

Holt

2014

Brit J Clinical Pharma

210

175

View full text Add to dashboard Cite

Poor-quality medicines present a serious public health problem, particularly in emerging economies and developing countries, and may have a significant impact on the national clinical and economic burden. Attention has largely focused on the increasing availability of deliberately falsified drugs, but substandard medicines are also reaching patients because of poor manufacturing and quality-control practices in the production of genuine drugs (either branded or generic). Substandard medicines are widespread and represent a threat to health because they can inadvertently lead to healthcare failures, such as antibiotic resistance and the spread of disease within a community, as well as death or additional illness in individuals. This article reviews the different aspects of substandard drug formulation that can occur (for example, pharmacological variability between drug batches or between generic and originator drugs, incorrect drug quantity and presence of impurities). The possible means of addressing substandard manufacturing practices are also discussed. A concerted effort is required on the part of governments, drug manufacturers, charities and healthcare providers to ensure that only drugs of acceptable quality reach the patient.

show abstract

“…However, even though generic drugs have the same active ingredients, they may differ with respect to inactive ingredients such as the adjuvant solution (Cantor 1997;Chambers 2012;Zore et al 2013). However, even though generic drugs have the same active ingredients, they may differ with respect to inactive ingredients such as the adjuvant solution (Cantor 1997;Chambers 2012;Zore et al 2013).…”

Section: Introductionmentioning

confidence: 99%

“…Without doubt, they can produce cost savings for both patients and the healthcare system. However, even though generic drugs have the same active ingredients, they may differ with respect to inactive ingredients such as the adjuvant solution (Cantor 1997;Chambers 2012;Zore et al 2013). This may affect factors such as pH, viscosity and buffer capacity and in turn pharmacokinetics, bioavailability and tolerability (Brechue & Maren 1993;Cantor 1997).…”

Section: Introductionmentioning

confidence: 99%